134 related articles for article (PubMed ID: 29552069)
1. CDKN2B Methylation Correlates with Survival in AML Patients.
Kamali Dolatabadi E; Ostadali Dehaghi M; Amirizadeh N; Parivar K; Mahdian R
Iran J Pharm Res; 2017; 16(4):1600-1611. PubMed ID: 29552069
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of
Park DJ; Kwon A; Cho BS; Kim HJ; Hwang KA; Kim M; Kim Y
Blood Res; 2020 Mar; 55(1):17-26. PubMed ID: 32269971
[TBL] [Abstract][Full Text] [Related]
4. Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia.
Chim CS; Kwong YL
Leuk Lymphoma; 2006 May; 47(5):815-25. PubMed ID: 16753865
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
6. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Am J Cancer Res; 2015; 5(6):2047-55. PubMed ID: 26269763
[TBL] [Abstract][Full Text] [Related]
7. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Am J Cancer Res; 2015; 5(5):1786-94. PubMed ID: 26175946
[TBL] [Abstract][Full Text] [Related]
8. Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene.
Candiloro IL; Mikeska T; Hokland P; Dobrovic A
Epigenetics Chromatin; 2008 Nov; 1(1):7. PubMed ID: 19014416
[TBL] [Abstract][Full Text] [Related]
9. Aberrant Methylation of APAF-1 Gene in Acute Myeloid Leukemia Patients.
Rostami S; Nadali F; Alibakhshi R; Zaker F; Nasiri N; Payandeh M; Chahardouli B; Maleki A
Int J Hematol Oncol Stem Cell Res; 2017 Jul; 11(3):225-230. PubMed ID: 28989589
[No Abstract] [Full Text] [Related]
10. Lower Levels of TET2 Gene Expression, with a Higher Level of TET2 Promoter Methylation in Patients with AML; Evidence for the Role of Aberrant Methylation in AML Pathogenesis.
Ghasemi B; Ahmadi J; Zaker F; Tabatabaei T; Kiani-Zadeh M; Kazemi A
Indian J Hematol Blood Transfus; 2024 Jan; 40(1):52-60. PubMed ID: 38312186
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia.
Guo H; Zhang TJ; Wen XM; Zhou JD; Ma JC; An C; Zhang W; Xu ZJ; Lin J; Qian J
Onco Targets Ther; 2017; 10():3635-3644. PubMed ID: 28790854
[TBL] [Abstract][Full Text] [Related]
12. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
[TBL] [Abstract][Full Text] [Related]
13. [Methylation Status and mRNA Expression of DKK-3 and WIF-1 in Acute Myeloid Leukemia Patients].
Xu MM; Yang YL; Geng YH; Li J; Ma Y; Zhang F; Zhu FB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1314-1320. PubMed ID: 29070101
[TBL] [Abstract][Full Text] [Related]
14. Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia.
Zhang ZH; Zhang W; Zhou JD; Zhang TJ; Ma JC; Xu ZJ; Lian XY; Wu DH; Wen XM; Deng ZQ; Lin J; Qian J
Mol Carcinog; 2018 Jun; 57(6):735-744. PubMed ID: 29457658
[TBL] [Abstract][Full Text] [Related]
15. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
[TBL] [Abstract][Full Text] [Related]
16. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
[TBL] [Abstract][Full Text] [Related]
17. Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.
Achille NJ; Othus M; Phelan K; Zhang S; Cooper K; Godwin JE; Appelbaum FR; Radich JP; Erba HP; Nand S; Zeleznik-Le NJ
Leuk Res; 2016 Mar; 42():68-74. PubMed ID: 26818573
[TBL] [Abstract][Full Text] [Related]
18. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
19. The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia.
Zhu XW; Wen XM; Zhang YY; Yang L; Guo H; Yang J; Zhang M; Yin JY; Ma JC; Lin J; Deng ZQ; Qian J
Int J Clin Exp Pathol; 2015; 8(5):4321-31. PubMed ID: 26191124
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia.
Lenz G; Hutter G; Hiddemann W; Dreyling M
Ann Hematol; 2004 Oct; 83(10):628-33. PubMed ID: 15309527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
